ESR1 and triple-negative breast carcinoma: We initially evaluated anti-proliferative activity of PP and PL against three human breast cell lines, including a triple-negative breast cancer (TNBC) cell line (MDA-MB-231), an ER/PR positive breast cancer cell line (MCF-7), and a normal cell line (MCF-10A).